Novartis Revises U.S. Regulatory Strategy For Key Respiratory Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss drug maker says it has agreed with FDA on a Phase III trial design for the combination respiratory drug QVA149 and expects to file in late 2014; plan now calls for testing a twice-daily dose in addition to once-daily.